McNicoll, Lewis & Vlak Maintains Aeterna Zentaris Buy, PT

McNicoll, Lewis & Vlak maintained its Aeterna Zentaris AEZS Buy rating and $5.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "This morning, Æterna Zentaris (AEZS; Last close: $1.89) announced positive top-line results of its Phase III trial of AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD)." Later in the report, McNicoll, Lewis & Vlak notes, "Given these strong results, we would expect discussions with potential commercialization partners to accelerate, though we do not expect that a partnership announcement is imminent. Importantly, given the small and discrete nature of this diagnostic market, the company has said that it is willing to commercialize the product itself, should it be deemed the most favorable option." Shares of Aeterna Zentaris were trading at $2.06 at the time of posting, up 8.99% from Monday's market close.